<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952939</url>
  </required_header>
  <id_info>
    <org_study_id>CASE5608</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE5608</secondary_id>
    <secondary_id>CASE 5608-CC666</secondary_id>
    <nct_id>NCT00952939</nct_id>
  </id_info>
  <brief_title>Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye</brief_title>
  <official_title>Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may&#xD;
      help doctors learn more about changes that occur in DNA and identify biomarkers related to&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying tumor samples in patients undergoing surgery or&#xD;
      radiation therapy for primary melanoma of the eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish the feasibility of using fine needle aspiration (FNA) and FISH to determine&#xD;
           tumor genotype in patients with primary uveal melanoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize ophthalmic complication rate of FNA for FISH analysis in patients&#xD;
           undergoing plaque radiotherapy.&#xD;
&#xD;
        -  To estimate disease-free survival in patients with and without tumor monosomy 3 and/or&#xD;
           8q amplification.&#xD;
&#xD;
        -  To explore the relationship between tumor monosomy 3 and 8q amplification and plasma&#xD;
           levels of tumor immune escape and invasion biomarkers (e.g., circulating granulysin,&#xD;
           beta2-microglobulin, autotoxin, lysophosphatidic acid, matrix metalloproteinase-7,&#xD;
           tissue inhibitor of matrix metalloproteinase, and soluble E- cadherin).&#xD;
&#xD;
        -  To explore the psychological impact of prognostication in uveal melanoma.&#xD;
&#xD;
      OUTLINE: Patients undergo plaque radiotherapy, enucleation, or tumor resection based upon&#xD;
      standard of care guidelines.&#xD;
&#xD;
      Trans-scleral fine needle aspiration (FNA) is performed at the time of plaque radiotherapy&#xD;
      and ex vivo FNA is performed on enucleation and tumor resection specimens. Tissue samples are&#xD;
      analyzed by fluorescence in situ hybridization (FISH). Blood samples are also collected for&#xD;
      further analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that have Disease Free Survival (DFS) with primary uveal melanoma with and without high-risk genotypes</measure>
    <time_frame>2 years</time_frame>
    <description>DFS will be measured from the date of initial treatment to the date of documented recurrence or death. It will be summarized using the method of Kaplan and Meier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events to determine ophthalmic complication rate of FNA for FISH analysis in patients undergoing plaque radiotherapy.</measure>
    <time_frame>2 years</time_frame>
    <description>To characterize ophthalmic complication rate of FNA for FISH analysis in patients undergoing plaque radiotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate that sufficient tissue can be obtained by FNA.</measure>
    <time_frame>2 yrs</time_frame>
    <description>Determine if sufficient material for FISH analysis can be obtained by transscleral FNA, a diagnostic procedure performed for a variety of clinical indications in patients with eye abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of particular markers at specific timepoints</measure>
    <time_frame>at baseline, multiple time points up to 2 years</time_frame>
    <description>Plasma will be analyzed for circulating granulysin, beta2-microglobulin, autotoxin, lysophosphatidic acid, matrix metalloproteinase-7, tissue inhibitor of matrix metalloproteinase, and soluble E-cadherin.</description>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Intraocular Melanoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
    <description>At time of surgery</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>At time of surgery</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fine-needle aspiration</intervention_name>
    <description>At time of surgery</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>At time of surgery</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.</description>
    <other_name>Hospital Anxiety and Depression Scale (HADS)</other_name>
    <other_name>Decision Regret Scale</other_name>
    <other_name>The MINI (a structured psychiatric interview)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients must have a clinical diagnosis of melanoma of the iris, ciliary body and/or&#xD;
             choroids&#xD;
&#xD;
          -  Patients must have had a hepatic ultrasound and/or other suitable imaging studies to&#xD;
             eliminate metastatic disease&#xD;
&#xD;
          -  Patients must not have received any local or systemic therapy for uveal melanoma&#xD;
&#xD;
          -  All patients must be informed of the investigational nature of this study and must&#xD;
             provide written informed consent in accordance with institutional and federal&#xD;
             guidelines. A copy of the informed consent document signed by the patient must be&#xD;
             given to the patient&#xD;
&#xD;
          -  Patients must have the following pretreatment laboratory findings:&#xD;
&#xD;
               -  Bilirubin (total) &lt;/= 1.5 ml/dl&#xD;
&#xD;
               -  AST &lt;/= 2 x normal&#xD;
&#xD;
               -  ALT &lt;/= 2 x normal&#xD;
&#xD;
               -  Alkaline phosphatase &lt;/= 2 x normal&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with metastasis&#xD;
&#xD;
          -  Patients under the age of 18&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun D. Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>January 28, 2015</last_update_submitted>
  <last_update_submitted_qc>January 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ciliary body and choroid melanoma, small size</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>intraocular melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

